Prelude Therapeutics price target raised to $6 from $3 at Citizens
Citizens raised the firm’s price target on Prelude Therapeutics (PRLD) to $6 from $3 and keeps an Outperform rating on the shares following the Q4 report. The preclinical JAK2V617F data support potential best-in-class selectivity and disease modifying potential, the analyst tells investors in a research note. Citizens believes Prelude shares “represent a unique investment opportunity with meaningful upside.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Read More on PRLD:
Disclaimer & DisclosureReport an Issue
- Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program
- Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year
- Prelude Therapeutics sees cash runway into 2Q27
- Prelude Therapeutics Wins FDA IND Clearance for PRT12396
- Prelude receives FDA clearance for investigational IND for PRT12396
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Solana Price Holds Range as $90 Resistance Caps Breakout
Bitcoin Leverage Builds as Price Stalls Below $80,000
BONE Network Heats Up: 93K Holders After Massive Weekly Surge
Michael Saylor teases Bitcoin buy, but bulls may get less
Trending news
MoreCrypto prices
More
